EMA Probes Link With Diabetes Drug Canagliflozin, Toe AmputationEMA Probes Link With Diabetes Drug Canagliflozin, Toe Amputation

The European Medicines Agency is reviewing the type 2 diabetes drug canagliflozin, an SGLT2 inhibitor, after an increase in toe amputations was observed in the ongoing CANVAS trial. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news